Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Deutsche Medizinische Wochenschrift (1946)|January 29, 2021
[Treatment of soft tissue sarcomas including GIST - Update 2021]Peter Reichardt, Daniel Pink
Current Cancer Drug Targets|May 24, 2011
Molecular targeted therapy of gastrointestinal stromal tumorsPeter Reichardt, Annette Reichardt, Daniel Pink
Zentralblatt Fur Chirurgie|April 9, 2020
[Systemic Therapy Options for Locally Advanced and Metastatic Myxoid, Dedifferentiated and Pleomorphic Liposarcoma]Daniel Pink, Antje West, Dimosthenis Andreou
Onkologie|August 8, 2012
Efficacy of trabectedin in patients with advanced or metastatic alveolar soft-part sarcomaDaniel Pink, Janina Bertz-Lepel, Christoph Busemann, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 8, 2024
Exploring the integration of dentistry within a multidisciplinary palliative care team: does bedside dental care improve quality of life and symptom burden in inpatient palliative care patients?Sarah Uhlig, Florian Doberschütz, Franziska Hallmann, et al.
Acta Orthopaedica|November 10, 2011
Survival and prognostic factors in chondrosarcoma: results in 115 patients with long-term follow-upDimosthenis Andreou, Sebastian Ruppin, Sebastian Fehlberg, et al.
Marine Drugs|January 16, 2015
Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG)Bernd Kasper, Peter Reichardt, Daniel Pink, et al.
Cancers|April 27, 2024
How Do Quality of Life (QoL) and Symptom Burden Evolve in Inpatient Palliative Care (PC) Patients following One Week of Care in a Specialized Palliative Care Unit (PCU)? A Comparison of Two Groups, with One Receiving Specialized Outpatient Palliative Care Prior to AdmissionHanna Salm, Florian Doberschütz, Franziska Hallmann, et al.
Cancer Investigation|January 11, 2025
Weather-Related Factors and Patient-Reported Outcomes (PROs) in Cancer Patients: Results from the ExPRO StudyHanna Salm, Martin Eichler, Jeanette Bahr, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|November 28, 2017
No indication of increased infection rates using low-dose alemtuzumab instead of anti-thymocyte globulin as graft-versus-host disease prophylaxis before allogeneic stem cell transplantationThomas Neumann, Laila Schneidewind, Thomas Thiele, et al.
Pageof 7